Development of therapeutic area investigated in clinical trials completed from 2008–2019. by Mette Brøgger-Mikkelsen (13154931)

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance by Peng He (24579)

Subjects:

Supplementary Figure 3 - Niraparib treatment increases DNA damage and decreases proliferation. from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsi... by Yevgen Chornenkyy (15072472)

Knockdown of Viperin reduced ddhCTP production and decreased CMPK2 antiviral activity. by Mingjun Zhu (5817179)

Idea and process of this research. by Peng Zhang (2071)

Figure 5 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma by Yichi Zhang (20458547)

“…<p>FAK nuclear localization supports KMF tumor cisplatin resistance <i>in vivo</i> with effects on downstream signaling. …”

The main research content of the article. by Jingxuan Wang (435196)

Subjects:

<i>CHGA</i> mRNA expression decreases with <i>CYB561</i> knockdown. by Romie Angelo G. Azur (18547651)

A potential therapeutic agent for sickle cell anaemia by Nature Research (16552612)

“…They also found increased levels of ROS that were associated with decreased levels of antioxidant enzymes and their co-factors.…”

Tumors from vehicle-treated mice were collected at the end of study, homogenized, and assessed for expression of FGFR1, vimentin, and β-actin. by Angela Abdollahi (15166230)

Low ATF3 expression is associated with decreased survival and EZH2 and ATF3 signatures inversely correlate in human prostate cancers. by Amy E. Schade (15368259)

Subjects:

NeuroD1/GPX4 axis promotes HCC cell ferroptosis resistance and tumorigenic potential. by Ping Huang (30439)

Subjects:

Image1_Therapeutic role of Wuda granule in gastrointestinal motility disorder through promoting gastrointestinal motility and decreasing inflammatory level.JPEG by Zhi Jiang (269212)

<i>CYB561</i> knockdown decreased the survival, proliferation, and migration rates of PC-3 cells. by Romie Angelo G. Azur (18547651)

NeuroD1 directly binds to the <i>GPX4</i> promoter and regulates its transcriptional activity in MHCC-97H cells. by Ping Huang (30439)

Subjects: